Loading News...
Back to Dashboard

10x Genomics, Inc. (TXG)

Real-time intraday values

Market Overview

From:
To:
TXG Intraday
No data available
SymbolTXG
IPO DateSep 12, 2019
CEODr. Serge Saxonov Ph.D.
Full Time Employees1.2k
SectorHealthcare
IndustryHealth Information Services
CountryUnited States
ExchangeNasdaqGS
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Performance
PeriodReturn %Value Change
1 Day
+1.68%
+0.54 US$
5 Days
+12.77%
+3.71 US$
1 Month
+54.53%
+11.56 US$
6 Months
+108.00%
+17.01 US$

Analyzing Market with AI

Evaluating the last 30 days of history and fundamental metrics of TXG...

Key Statistics
Market Cap
4.16B
P/E Ratio
N/A
Div Yield
N/A
52W High
$35.65
52W Low
$10.38

Analyst Consensus

ConsensusBuy
Bullish637.5%
Neutral1062.5%
Bearish00.0%

52W Analyst Price Targets

Min Target
$20.00
Max Target
$32.00
Current$32.76
Avg Target$25.77

Analyst Recommendations

Target Price:$25.77($20.00 - $32.00)
FirmRatingTarget PriceUpside PotentialDate
Morgan StanleyEqual-Weight$22.00-32.84%5/12/2026
JP MorganNeutral$20.00-38.95%5/12/2026
Canaccord GenuityBuy$32.00-2.32%4/20/2026
B of A SecuritiesNeutral$30.00-8.42%4/20/2026
BarclaysOverweight$30.00-8.42%4/14/2026
CitigroupNeutral$24.00-26.74%4/7/2026
William BlairOutperform$0.00-100.00%3/31/2026
StifelBuy$25.00-23.69%3/2/2026
UBSNeutral$20.00-38.95%2/20/2026
StifelBuy$20.00-38.95%2/13/2026
Community Thoughts

Share your analysis and sentiment on TXG

Join the community to share your analysis